[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622120":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":10,"centralContacts":21,"locations":10,"responsibleParty":27,"collaborators":10,"id":31,"slug":10,"hasResults":32,"nctId":33,"briefTitle":34,"officialTitle":35,"acronym":10,"eligibilityCriteria":36,"healthyVolunteers":32,"sex":37,"minAge":38,"maxAge":39,"enrollmentInfo":40,"targetDuration":10,"studyType":43,"phases":10,"briefSummary":44,"conditions":45,"keywords":10,"overallStatus":50,"whyStopped":10,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":10},{"fullName":5,"class":6},"Tongji Hospital","OTHER",[8,11],{"label":9,"type":10,"description":10,"interventionNames":10},"Active surveillance cohort",null,{"label":12,"type":10,"description":10,"interventionNames":13},"Adjuvant PD-1 inhibitor cohort",[14],"Drug: PD-1 Inhibitors",[16],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":10},"DRUG","PD-1 Inhibitors","Patients in the adjuvant cohort received at least one cycle of PD-1 inhibitors.",[12],[22],{"name":23,"role":24,"phone":25,"phoneExt":10,"email":26},"Wanguang Zhang, PhD","CONTACT","+8613886195965","wgzhang@tjh.tjmu.edu.cn",{"type":28,"investigatorFullName":29,"investigatorTitle":30,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Wan-Guang Zhang","Professor","100622120",false,"NCT07379489","Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma","Efficacy of Postoperative Adjuvant PD-1 Inhibitors Guided by a Deep Learning Model: a Multicenter, Prospective Cohort Study","Inclusion Criteria:\n\n* Aged between 18 and 75;\n* achieved complete tumor resection;\n* histological verification of HCC;\n* liver function classified as Child-Pugh grade A or B;\n* No other serious systemic disease or organ dysfunction.\n\nExclusion Criteria:\n\n* history of other malignancies or recurrent HCC;\n* extrahepatic metastasis;\n* prior treatments for HCC;\n* ongoing severe postoperative complications;\n* mixed or other types of liver cancer;\n* received other adjuvant therapy.","ALL","18 Years","75 Years",{"count":41,"type":42},300,"ESTIMATED","OBSERVATIONAL","Early hepatocellular carcinoma (HCC) recurrence (driven by residual tumors) and late recurrence (driven by de novo tumors) exhibit distinct biological behaviors, suggesting differential therapeutic vulnerabilities. The beneficiaries of adjuvant PD-1 inhibitors (aPD-1) and their efficacy across these temporally divergent recurrence patterns remains unestablished.",[46,47,48,49],"HCC","Adjuvant Therapy","Recurrence","Immune Checkpoint Inhibitor","NOT_YET_RECRUITING","2026-01-23",{"date":53,"type":54},"2026-01-30","ACTUAL",{"date":56,"type":42},"2026-01-31",{"date":58,"type":42},"2031-12-31",{"name":5,"class":6}]